Insilico Medicine's Rentosertib Inhalation Solution Receives IND Clearance for First AI-Driven Direct-to-Lung Clinical Trial

Key Takeaways

• Rentosertib inhalation solution becomes the first AI-discovered drug to enter direct-to-lung clinical trials after receiving IND clearance from China’s CDE
• The inhalation formulation targets lung delivery for higher local bioavailability and reduced systemic side effects compared to oral administration
• This represents the 13th clinical program from Insilico Medicine’s AI-driven drug discovery platform, building on positive Phase IIa oral trial results

---

Insilico Medicine Advances AI Drug Discovery with Rentosertib Inhalation Trial

Insilico Medicine has achieved a significant milestone in artificial intelligence-driven drug development, receiving Investigational New Drug (IND) clearance from China’s Center for Drug Evaluation (CDE) for its Rentosertib inhalation solution. This approval marks the world’s first AI-discovered drug candidate to enter direct-to-lung clinical studies.

Building on Promising Oral Trial Results

The inhalation formulation development follows encouraging Phase IIa results from the GENESIS-IPF study, where oral Rentosertib demonstrated good tolerability, favorable pharmacokinetic profiles, and dose-dependent efficacy improvements in patients with idiopathic pulmonary fibrosis (IPF).

Targeted Lung Delivery Advantages

The inhalation solution represents a strategic advancement in drug delivery technology, designed to achieve several key benefits:

• Rapid onset of action through direct lung targeting
• Higher local bioavailability at the site of disease
• Lower required doses compared to systemic administration
• Reduced systemic exposure and associated side effects

This targeted approach addresses common challenges in treating pulmonary diseases, where achieving adequate drug concentrations in lung tissue while minimizing systemic toxicity remains a critical balance.

AI-Driven Pipeline Expansion

Rentosertib inhalation solution represents the 13th program emerging from Insilico Medicine’s AI-powered drug discovery platform, demonstrating the scalability and productivity of computational drug development approaches. The company’s artificial intelligence platform has successfully identified and advanced multiple drug candidates across various therapeutic areas.

Market Impact and Future Implications

This regulatory milestone reinforces the growing acceptance of AI-discovered therapeutics in clinical development. The direct-to-lung delivery approach could potentially improve treatment outcomes for patients with pulmonary fibrosis and other respiratory conditions, representing a significant advancement in precision medicine approaches.

The successful transition from oral to inhalation formulation also demonstrates Insilico’s comprehensive drug development capabilities, extending beyond initial discovery to optimized delivery mechanisms that enhance therapeutic potential while improving patient safety profiles.

---

Frequently Asked Questions

What does this IND clearance mean for patients with pulmonary fibrosis?

The IND clearance allows Insilico to begin clinical trials testing Rentosertib as an inhalation treatment, which could potentially offer better lung targeting and fewer side effects than oral medications for IPF patients.

When will Rentosertib inhalation solution be available to patients?

The drug is just entering clinical trials, so availability depends on successful completion of Phase I, II, and III studies plus regulatory approval, which typically takes several years.

How does inhalation delivery compare to oral Rentosertib treatment?

Inhalation delivery is designed to provide higher drug concentrations directly in the lungs with lower overall doses, potentially reducing systemic side effects while maintaining or improving therapeutic benefits compared to oral administration.